21 patents
Utility
Bicyclic pyridazinones and methods of use thereof
2 Jan 24
David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
Filed: 5 Nov 21
Utility
Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B
19 Dec 23
Sandrine Vendeville, Yannick Debing, Antitsa Dimitrova Stoycheva, Pierre Jean-Marie Bernard Raboisson
Filed: 13 Oct 21
Utility
Modulators of THR-β and methods of use thereof
12 Dec 23
David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval
Filed: 8 Jul 21
Utility
Tricyclic compounds
21 Nov 23
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, Yannick Debing, Pierre Jean-Marie Bernard Raboisson
Filed: 22 Nov 21
Utility
Oxindoles and methods of use thereof
24 Oct 23
David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
Filed: 5 Nov 21
Utility
2-pyridones and methods of use thereof
17 Oct 23
David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
Filed: 5 Nov 21
Utility
Modified cyclic dinucleoside compounds as sting modulators
17 Oct 23
Provided herein are compounds of Formula (I), Formula (II) and/or Formula (III), or pharmaceutically acceptable salts of any of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Leonid Beigelman, Santhosh Kumar Thatikonda, Antitsa Dimitrova Stoycheva
Filed: 6 May 20
Utility
Pyrrole compounds
3 Oct 23
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, David Bernard Smith, Leonid Beigelman, Vladimir Serebryany
Filed: 16 Nov 21
Utility
Methods and compositions for targeting PD-L1
19 Sep 23
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction.
Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Francois Gonzalvez, Antitsa Dimitrova Stoycheva, Jerome Deval, Cheng Liu, Qingling Zhang
Filed: 12 Aug 21
Utility
Methods and compositions for targeting PD-L1
19 Sep 23
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction.
Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Antitsa Dimitrova Stoycheva, Francois Gonzalvez, Jerome Deval, Cheng Liu
Filed: 19 May 21
Utility
Methods of reducing virus molecule levels
28 Mar 23
Methods of reducing levels of virus molecules and/or treating viral infections include contacting cells with an oligonucleotide inhibitor that targets a cellular host factor that is a target RNA or target protein involved in viral replication.
Chia-Cheng Kao, Lawrence M. Blatt, Leonid Beigelman
Filed: 6 Nov 20
Utility
Bicyclic and tricyclic compounds
28 Feb 23
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, Pierre Jean-Marie Bernard Raboisson, Yannick Debing
Filed: 15 Apr 20
Utility
Modified short interfering nucleic acid (siNA) molecules and uses thereof
10 Jan 23
Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof.
Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
Filed: 15 Feb 22
Utility
Heterocyclic compounds
11 Oct 22
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, Pierre Jean-Marie Bernard Raboisson
Filed: 3 Jun 20
Utility
Modified gapmer oligonucleotides and methods of use
11 Oct 22
The disclosure includes antisense oligonucleotides, including gapmer antisense oligonucleotides, along with methods of making and use, e.g., against HBV.
Leonid Beigelman, Rajendra K. Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Jin Hong
Filed: 29 May 20
Utility
Compounds targeting PRMT5
14 Dec 21
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing
Filed: 31 Mar 20
Utility
Pyrrole compounds
7 Dec 21
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, David Bernard Smith, Leonid Beigelman, Vladimir Serebryany
Filed: 1 Apr 20
Utility
S-antigen transport inhibiting oligonucleotide polymers and methods
9 Nov 21
Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions.
Leonid Beigelman, Rajendra Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Lawrence M. Blatt, Jin Hong
Filed: 11 Sep 20
Utility
Tricyclic compounds
5 Oct 21
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville
Filed: 27 May 20
Utility
Modulators of THR-β and methods of use thereof
17 Aug 21
Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, David McGowan, Jerome Deval
Filed: 7 May 20